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The incidence of mumps in the Netherlands has increased since 
August 2007. Until mid May 2008, 89 individuals were found 
positive for mumps virus infection by laboratory testing at the 
Centre for Infectious Diseases Control (CIb) of the Dutch National 
Institute for Public Health and the Environment (RIVM), compared 
to less than 10 cases per year between 2005 and 2007. Mumps 
is not a notifiable disease in the Netherlands and surveillance 
is mainly based on monitoring laboratory test requests and their 
results offered by the CIb and other laboratories. As only a minority 
of cases is offered laboratory testing, however, the extent of the 
current mumps outbreak is unknown.
Background
Mumps is an acute infectious disease caused by an enveloped 
RNA virus that belongs to the genus Rubulavirus in the family 
Paramyxoviridae [1]. It is endemic worldwide and can occasionally 
cause outbreaks. The introduction of mumps vaccination has led to 
a decrease of mumps cases in the Netherlands since the late 1980s. 
Some 30% of mumps infections remain asymptomatic. Clinical 
manifestations include parotitis, often after a short prodromal 
phase of low-grade fever, malaise, anorexia and headache. The 
most common complications are meningitis, epididymo-orchitis, 
orchitis, oophoritis and encephalitis [2].
Mumps vaccination in the Netherlands has since 1987 been 
available through the national immunisation programme which 
includes the measles-mumps-rubella vaccine (MMR). This vaccine 
contains the Jeryl-Lynn mumps JL2 and JL5 vaccine strains, 
produced by the Netherlands Vaccine Institute (NVI) under licence 
of MSD. The first vaccination is scheduled at the age of 14 months 
with a second dose at the age of nine years. Since the introduction 
of the vaccine, less than 50 cases have been reported and only few 
patients with mumps have been admitted to a hospital annually 
[3,4]. The circulation of mumps virus in the Netherlands appears 
to have been very limited since 1987.
Mumps outbreak in the Netherlands 2007/2008
The median age of the laboratory confirmed mumps cases 
diagnosed at the CIb between 1 August 2007 and 15 May 2008 
(n=89) was 13 years (range 2-56 years). Fifty-five (62%) of the 
reported cases were males. We do not yet have a clear overview 
about complications attributable to mumps. 
The geographic distribution of the cases is shown in Figure 1. 
The cases are mostly resident in low vaccination coverage areas 
in the so-called Bible Belt (see Figure 2); the cluster in the south 
of the country involved anthroposophists. Another recent outbreak 
involving anthroposophists (in that case it was an outbreak of 
measles) has been reported in Austria, Germany and Norway [5].
Of 87 cases whose vaccination status is known, 58 (67%) were 
unvaccinated and 29 (33%) were vaccinated (13 cases vaccinated 
once and eight cases twice). Five cases (6%) were too old to have 
been vaccinated. For 39 unvaccinated cases who would have 
been eligible for vaccination, the reasons for non-vaccination were 
clearly stated. For 36 (92%) of them, the main reason for not being 
vaccinated was religion; all 36 were orthodox Reformed Christians. 
The estimated proportion of vaccinated cases is thought to be 
biased because laboratory testing was recommended preferentially 
for patients with a history of mumps vaccination.
Genotype D was the most frequently isolated genotype among 
the cases studied so far. Vaccinated cases were predominantly 
confirmed by PCR, while unvaccinated cases were confirmed both 
by PCR and by mumps virus specific IgM testing.
Discussion
Mumps outbreaks have been reported during the last years 
throughout Europe [6-10] and elsewhere [11]. In the Netherlands, 
a large mumps outbreak occurred in 2004 at an international 
school, with an attack rate of 12% among students vaccinated 
according to the Dutch schedule [Brockhoff, unpublished data]. 
The high rate of vaccine failure in the outbreak described here 
may have been related to a high force of infection at the school 
campus. However, it does raise concern about the effectiveness of 
mumps vaccination in the Netherlands.
The use of any of the 11 known vaccine strains, except Rubini, 
is supported by the WHO [12]. However, in recent years, evidence 
has accumulated for relatively frequent mumps vaccine failure, 
leading to doubts about the long-term effectiveness of mumps 
vaccines. Two-dose mumps vaccine failure caused a large mumps 
outbreak in the United States in 2006, with over 6,000 cases, the 
majority (63%) of whom had been vaccinated twice [10]. Possible 
explanations for this include waning immunity, possible mismatches 
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between the vaccine strain and a circulating wild-type virus strains 
and the absence of boosting due to natural infection. 
During a large outbreak in the United Kingdom (UK) in 2004-
2005, some evidence of waning immunity was found with the 
estimated vaccine effectiveness declining from 99% in five- to 
six-year-olds to 86% in 11- to 12-year-olds [13] (the UK Childhood 
Vaccination Schedule advises MMR vaccination at the age of 13 
months and four years). Recent data from a nationwide mumps 
outbreak in Moldova in 2007 and 2008 found that a high proportion 
of cases had been vaccinated with one dose in the past [9].
A number of outbreaks of vaccine-preventable diseases have 
been described in the Dutch Bible Belt in the past. A poliomyelitis 
outbreak occurred among unvaccinated individuals in 1978 and 
between 1992 and 1993 in the area, involving 110 and 71 
patients, respectively
[14,15]. In 1999-2000, a widespread measles outbreak 
occurred in the same area, involving 3,292 reported cases, most of 
whom were not vaccinated [16]. More recently, in 2004, the same 
area was home to a large rubella outbreak that lead to at least 11 
congenitally infections with birth defects, and that outbreak spread 
to Canada [17, and S. Hahné, personal communication]. As the 
vaccination coverage continues to be below recommended levels, 
further outbreaks of vaccine-preventable diseases are expected in 
this region [18].
The current situation, with a large outbreak in unvaccinated 
individuals and some spread to those vaccinated, provides a 
unique opportunity for further research on the mumps vaccine 
effectiveness, 20 years after the introduction of mumps vaccination 
in the Netherlands. However, routinely available data on the 
mumps outbreak does not allow unbiased estimation of the attack 
rates among vaccinated and unvaccinated population and the 
vaccine effectiveness. We are therefore planning an analytical 
epidemiological study including laboratory investigations.
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Geographical distribution of measles-mumps-rubella vaccination 
coverage by municipality at the age of two years in the Netherlands, 2008
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